In another study [101] involving 180 patients with ALK-positive ALCL who underwent second-line therapy, patients defined as MRD-positive based on CTCs had significantly lower 5-year survival rates and event-free survival compared to MRD-negative patients, and had a higher risk of relapse. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.